Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAL 0119

Next Previous
Drug Profile

SAL 0119

Alternative Names: SAL-0119

Latest Information Update: 17 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Salubris Pharmaceuticals
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase 14 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Ankylosing spondylitis

Most Recent Events

  • 18 Oct 2023 Shenzhen Salubris Pharmaceuticals initiates phase I clinical trials in Rheumatoid arthritis (In volunteers) in China (PO) (CTR20232935)
  • 17 Jul 2023 USFDA approves IND application for SAL 0119 in rheumatoid arthritis
  • 15 May 2023 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in China (PO) (CTR20231254)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top